Abstract |
Patients with low grade (LG) non-Hodgkin's lymphomas (NHLs) typically have a median survival of 8-10 years during which they sustain a series of responses and relapses to therapy. More than 95% of B-cell NHLs express the CD20 surface antigen, affording opportunities for CD20-directed therapy of NHL. Since 1990, 5 trials have tested the safety and efficacy of the murine CD20 MAb Tositumomab and Iodine I 131 Tositumomab ( Bexxar therapeutic regimen) in 250 patients with relapsed, refractory, or transformed LG NHL. The I-131 irradiates MAb-bound cells and those within the path length of the isotope. Response rates were 56% (overall) and 30% (complete). With a median follow-up of 44.6 months, 30% of the patients achieved a long-term, durable response; median time to progressive disease or death was 5 years. Thus, a single treatment with Bexxar may produce durable responses and partially reverse the natural history of LG NHL.
|
Authors | Robert L Capizzi |
Journal | Transactions of the American Clinical and Climatological Association
(Trans Am Clin Climatol Assoc)
Vol. 115
Pg. 255-72
( 2004)
ISSN: 0065-7778 [Print] United States |
PMID | 17060972
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Antigens, CD20
- Iodine Radioisotopes
- tositumomab I-131
|
Topics |
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antigens, CD20
(metabolism)
- Clinical Trials as Topic
- Humans
- Iodine Radioisotopes
(therapeutic use)
- Lymphoma, B-Cell
(therapy)
- Lymphoma, Non-Hodgkin
(classification, pathology, therapy)
- Neoplasm Staging
- Radioimmunotherapy
- Remission Induction
|